Literature DB >> 20188202

Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation.

David A Rizzieri1, Robert Storms, Dong-Feng Chen, Gwynn Long, Yiping Yang, Daniel A Nikcevich, Cristina Gasparetto, Mitchell Horwitz, John Chute, Keith Sullivan, Therese Hennig, Debashish Misra, Christine Apple, Megan Baker, Ashley Morris, Patrick G Green, Vic Hasselblad, Nelson J Chao.   

Abstract

Infusing natural killer (NK) cells following transplantation may allow less infections and relapse with little risk of acute graft-versus-host disease (aGVHD). We delivered 51 total NK cell-enriched donor lymphocyte infusions (DLIs) to 30 patients following a 3-6/6 HLA matched T cell-depleted nonmyeloablative allogeneic transplant. The primary endpoint of this study was feasibility and safety. Eight weeks following transplantation, donor NK cell-enriched DLIs were processed using a CD56(+) selecting column with up to 3 fresh infusions allowed. Toxicity, relapse, and survival were monitored. T cell phenotype, NK cell functional recovery, and KIR typing were assessed for association with outcomes. Fourteen matched and 16 mismatched transplanted patients received a total of 51 NK cell-enriched DLIs. Selection resulted in 96% (standard deviation [SD] 8%) purity and 83% (SD 21%) yield in the matched setting and 97% (SD 3%) purity and 77% (SD 24%) yield in the mismatched setting. The median number of CD3(-) CD56(+) NK cells infused was 10.6 (SD 7.91) x 10(6) cells/kg and 9.21 (SD 5.6) x 10(6) cells/kg, respectively. The median number of contaminating CD3(+)CD56(-) T cells infused was .53 (1.1) x 10(6) and .27 (.78) x 10(6) in the matched and mismatched setting, respectively. Only 1 patient each in the matched (n = 14) or mismatched (n = 16) setting experienced severe aGVHD with little other toxicity attributable to the infusions. Long-term responders with multiple NK cell-enriched infusions and improved T cell phenotypic recovery had improved duration of responses (p = .0045) and overall survival (OS) (P = .0058). A 1-step, high-yield process is feasible, and results in high doses of NK cells infused with little toxicity. NK cell-enriched DLIs result in improved immune recovery and outcomes for some. Future studies must assess whether the improved outcomes are the direct result of the high doses and improved NK cell function or other aspects of immune recovery.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20188202      PMCID: PMC3625653          DOI: 10.1016/j.bbmt.2010.02.018

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  33 in total

1.  Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen.

Authors:  D A Rizzieri; G D Long; J J Vredenburgh; C Gasparetto; A Morris; T T Stenzel; P Davis; N J Chao
Journal:  Blood       Date:  2001-12-01       Impact factor: 22.113

2.  Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications.

Authors:  Emma C Morris; Peppy Rebello; Kirsty J Thomson; Karl S Peggs; Charalampia Kyriakou; Anthony H Goldstone; Stephen Mackinnon; Geoff Hale
Journal:  Blood       Date:  2003-03-06       Impact factor: 22.113

Review 3.  The biology of human natural killer-cell subsets.

Authors:  M A Cooper; T A Fehniger; M A Caligiuri
Journal:  Trends Immunol       Date:  2001-11       Impact factor: 16.687

4.  Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.

Authors:  R Childs; A Chernoff; N Contentin; E Bahceci; D Schrump; S Leitman; E J Read; J Tisdale; C Dunbar; W M Linehan; N S Young; A J Barrett
Journal:  N Engl J Med       Date:  2000-09-14       Impact factor: 91.245

5.  Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.

Authors:  Loredana Ruggeri; Marusca Capanni; Elena Urbani; Katia Perruccio; Warren D Shlomchik; Antonella Tosti; Sabrina Posati; Daniela Rogaia; Francesco Frassoni; Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Science       Date:  2002-03-15       Impact factor: 47.728

6.  Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose.

Authors:  W R Drobyski; C A Keever; M S Roth; S Koethe; G Hanson; P McFadden; J L Gottschall; R C Ash; P van Tuinen; M M Horowitz
Journal:  Blood       Date:  1993-10-15       Impact factor: 22.113

7.  Autologous natural killer cell therapy for human recurrent malignant glioma.

Authors:  Eiichi Ishikawa; Koji Tsuboi; Kaoru Saijo; Hideki Harada; Shingo Takano; Tadao Nose; Tadao Ohno
Journal:  Anticancer Res       Date:  2004 May-Jun       Impact factor: 2.480

Review 8.  NK cells: innate immunity against hematological malignancies?

Authors:  Régis T Costello; Cyril Fauriat; Simona Sivori; Emanuela Marcenaro; Daniel Olive
Journal:  Trends Immunol       Date:  2004-06       Impact factor: 16.687

Review 9.  Immunotherapy of cancer for the elderly patient: does allogeneic bone marrow transplantation after nonmyeloablative conditioning provide a new option?

Authors:  Margot Zöller
Journal:  Cancer Immunol Immunother       Date:  2004-04-06       Impact factor: 6.968

Review 10.  Alloreactive killer cells: hindrance and help for haematopoietic transplants.

Authors:  Peter Parham; Karina L McQueen
Journal:  Nat Rev Immunol       Date:  2003-02       Impact factor: 53.106

View more
  34 in total

1.  Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions.

Authors:  Hans Klingemann; Carrie Grodman; Elliott Cutler; Marvin Duque; Diane Kadidlo; Andreas K Klein; Kellie A Sprague; Kenneth B Miller; Raymond L Comenzo; Tarun Kewalramani; Neng Yu; Richard A Van Etten; David H McKenna
Journal:  Transfusion       Date:  2012-06-28       Impact factor: 3.157

Review 2.  Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease.

Authors:  James O J Davies; Kate Stringaris; A John Barrett; Katayoun Rezvani
Journal:  Cytotherapy       Date:  2014-05-20       Impact factor: 5.414

Review 3.  Haploidentical hematopoietic transplantation without T-cell depletion: current status and future perspectives.

Authors:  Lei Gao; Xi Zhang
Journal:  Stem Cell Investig       Date:  2015-10-20

Review 4.  Challenges of NK cell-based immunotherapy in the new era.

Authors:  Fang Fang; Weihua Xiao; Zhigang Tian
Journal:  Front Med       Date:  2018-07-25       Impact factor: 4.592

Review 5.  Clinical utility of natural killer cells in cancer therapy and transplantation.

Authors:  David A Knorr; Veronika Bachanova; Michael R Verneris; Jeffrey S Miller
Journal:  Semin Immunol       Date:  2014-03-05       Impact factor: 11.130

6.  Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation.

Authors:  Stefan O Ciurea; Jolie R Schafer; Roland Bassett; Cecele J Denman; Kai Cao; Dana Willis; Gabriela Rondon; Julianne Chen; Doris Soebbing; Indreshpal Kaur; Alison Gulbis; Sairah Ahmed; Katayoun Rezvani; Elizabeth J Shpall; Dean A Lee; Richard E Champlin
Journal:  Blood       Date:  2017-08-23       Impact factor: 22.113

Review 7.  Alemtuzumab for the prevention and treatment of graft-versus-host disease.

Authors:  Junya Kanda; Richard D Lopez; David A Rizzieri
Journal:  Int J Hematol       Date:  2011-03-03       Impact factor: 2.490

8.  Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors.

Authors:  David A Rizzieri; Christopher Crout; Robert Storms; Jared Golob; Gwynn D Long; Cristina Gasparetto; Keith M Sullivan; Mitchell Horwitz; John Chute; Anand S Lagoo; Ashley Morris; Anne Beaven; Yiping Yang; Bercedis Peterson; Zhiguo Li; Nelson J Chao
Journal:  Cancer Invest       Date:  2011-01       Impact factor: 2.176

9.  Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.

Authors:  Dean A Lee; Cecele J Denman; Gabriela Rondon; Glenda Woodworth; Julianne Chen; Tobi Fisher; Indreshpal Kaur; Marcelo Fernandez-Vina; Kai Cao; Stefan Ciurea; Elizabeth J Shpall; Richard E Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2016-04-16       Impact factor: 5.742

Review 10.  NK cell-based immunotherapy for malignant diseases.

Authors:  Min Cheng; Yongyan Chen; Weihua Xiao; Rui Sun; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2013-04-22       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.